Show simple item record

dc.contributor.authorPrice, S
dc.contributor.authorWiering, B
dc.contributor.authorMounce, LTA
dc.contributor.authorHamilton, W
dc.contributor.authorAbel, G
dc.date.accessioned2022-12-12T11:05:10Z
dc.date.issued2022-12-09
dc.date.updated2022-12-12T10:18:47Z
dc.description.abstractBackground Current methods for estimating the timeliness of cancer diagnosis are not robust because dates of key defining milestones, for example first presentation, are uncertain. This is exacerbated when patients have other conditions (multimorbidity), particularly those that share symptoms with cancer. Methods independent of this uncertainty are needed for accurate estimates of the timeliness of cancer diagnosis, and to understand how multimorbidity impacts the diagnostic process. Methods Participants were diagnosed with oesophagogastric cancer between 2010 and 2019. Controls were matched on year of birth, sex, general practice and multimorbidity burden calculated using the Cambridge Multimorbidity Score. Primary care data (Clinical Practice Research Datalink) was used to explore population-level consultation rates for up to two years before diagnosis across different multimorbidity burdens. Five approaches were compared on the timing of the consultation frequency increase, the inflection point for different multimorbidity burdens, different aggregated time-periods and sample sizes. Results We included 15,410 participants, of which 13,328 (86.5 %) had a measurable multimorbidity burden. Our new maximum likelihood estimation method found evidence that the inflection point in consultation frequency varied with multimorbidity burden, from 154 days (95 %CI 131.8–176.2) before diagnosis for patients with no multimorbidity, to 126 days (108.5–143.5) for patients with the greatest multimorbidity burden. Inflection points identified using alternative methods were closer to diagnosis for up to three burden groups. Sample size reduction and changing the aggregation period resulted in inflection points closer to diagnosis, with the smallest change for the maximum likelihood method. Discussion Existing methods to identify changes in consultation rates can introduce substantial bias which depends on sample size and aggregation period. The direct maximum likelihood method was less prone to this bias than other methods and offers a robust, population-level alternative for estimating the timeliness of cancer diagnosis.en_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.description.sponsorshipCancer Research UKen_GB
dc.format.extent102310-102310
dc.identifier.citationVol. 82, article 102310en_GB
dc.identifier.doihttps://doi.org/10.1016/j.canep.2022.102310
dc.identifier.grantnumberPRU-1217-21601en_GB
dc.identifier.grantnumberC8640/A23385en_GB
dc.identifier.urihttp://hdl.handle.net/10871/132001
dc.identifierORCID: 0000-0002-2228-2374 (Price, Sarah)
dc.identifierScopusID: 57195915869 (Price, Sarah)
dc.identifierResearcherID: D-2641-2016 (Price, Sarah)
dc.identifierORCID: 0000-0002-6089-0661 (Mounce, Luke TA)
dc.identifierORCID: 0000-0003-1611-1373 (Hamilton, Willie)
dc.identifierScopusID: 55031252700 | 57209301809 (Hamilton, Willie)
dc.identifierResearcherID: G-8612-2014 (Hamilton, Willie)
dc.identifierORCID: 0000-0003-2231-5161 (Abel, Gary)
dc.identifierScopusID: 57202757335 (Abel, Gary)
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rights/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en_GB
dc.subjectEarly diagnosis of canceren_GB
dc.subjectMethodological studyen_GB
dc.subjectMaximum likelihood estimatesen_GB
dc.titleExamining methodology to identify patterns of consulting in primary care for different groups of patients before a diagnosis of cancer: An exemplar applied to oesophagogastric canceren_GB
dc.typeArticleen_GB
dc.date.available2022-12-12T11:05:10Z
dc.identifier.issn1877-7821
exeter.article-number102310
dc.descriptionThis is the final version. Available on open access from Elsevier via the DOI in this recorden_GB
dc.identifier.journalCancer Epidemiologyen_GB
dc.relation.ispartofCancer Epidemiology, 82
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2022-11-30
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-12-09
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-12-12T11:03:12Z
refterms.versionFCDVoR
refterms.dateFOA2022-12-12T11:05:14Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's licence is described as /© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).